Abstract
In May 2006, AstraZeneca decided to stop the production of quinidine sulfate.1 Consequently, it is becoming increasingly difficult to obtain quinidine supplies in many countries. To our knowledge, neither the Heart Rhythm Society nor the European Heart Rhythm Association was informed in advance of this decision. According to the web-page posted by AstraZeneca,1 the decision to cease production was taken ‘as the demand for their quinidine product declined considerably due to the availability of newer, more effective alternatives’. Indeed, newer class IC and class III drugs replaced quinidine in the treatment of atrial fibrillation, whereas the implantable cardioverter defibrillator (ICD) replaced practically all antiarrhythmic drugs in the treatment of ventricular arrhythmias associated with … *Corresponding author. Tel: +972 3 6974413; fax: +972 3 6974416. E-mail address : saviskin{at}tasmc.health.gov.il
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
